https://doi.org/10.4081/hmr.v2i13.490

Alemtuzumab (Campath-1H)

Vol. 2 No. 13: It’s time to take care of T-Cell Lymphomas Bologna, Italy, 22-24 October 2006
Published: June 10, 2009
Abstract Views: 157
PDF: 232
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

C Querfeld
support@pagepress.org
TM Kuzel
J Guitart
ST Rosen
Monoclonal antibodies (MoAb) augment the host anti-tumor response by selectively targeting the malignant cells. MoAb can mediate anti-tumor effects through three major mechanisms including intrinsic cytotoxic activity, antibody-dependent cellular cytotoxicity (ADCC), and activation of complement-dependent cytolysis. Alemtuzumab is a humanized IgG1 MoAb that targets the glycosylated peptide cell surface antigen CD52 that is abundantly expressed (approximately 500,000 molecules/cell) on normal and malignant B- and T-cells, but not on hemat o poietic stem cells. It was approved by the US Food and Drug Administration (FDA) in 2001 for the treatment of refractory B-cell chronic lymphocytic leukemia (B-CLL).

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Querfeld, C., Kuzel, T., Guitart, J., & Rosen, S. (2009). Alemtuzumab (Campath-1H). Hematology Meeting Reports (formerly Haematologica Reports), 2(13). https://doi.org/10.4081/hmr.v2i13.490
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).